Masitinib
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071752
CAS NO.790299-79-5
Purity 98+%
MDL NumberMFCD09954132
Molecular Formula C28H30N6Os
Molecular Weight 498.652
| Category | Content |
|---|---|
| Generic Name | Masitinib |
| Brand Name | Masivet, Kinavet, Alsitek (proposed for ALS) |
| Chemical Formula | C28H30N6OS |
| CAS Number | 790299-79-5 |
| Mechanism of Action | Masitinib is a selective tyrosine kinase inhibitor targeting c-Kit, PDGFR, Lyn, FAK, FGFR3, and CSF1R. It also inhibits SARS-CoV-2 3CLpro. |
| Indications | – Approved for treating mast cell tumors in dogs.<br>- Investigated for various human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer.<br>- Studied in neurodegenerative diseases like ALS, Alzheimer’s disease, and multiple sclerosis.<br>- Under investigation for COVID-19. |
| Dosage Forms | Oral tablets. |
| Administration | – For ALS: 4.5-6 mg/kg/day, orally twice daily.<br>- For other indications: Dosing varies based on clinical trials and specific conditions. |
| Clinical Trials | – Completed Phase 2b/3 trial in ALS.<br>- Ongoing Phase 3 trial in ALS.<br>- Phase 3 trials in progressive multiple sclerosis. |
| Regulatory Status | – Orphan drug designation for ALS and pancreatic cancer in the US and Europe.<br>- Conditional approval applications filed in Canada and the EU for ALS. |
| Developer | AB Science |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
